Specific binding members for TGFbeta1
The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor 1 (TGF ). More particularly, the invention is concerned with specific binding members which include the VH CDR3 of the antibody SL15 (the antibody former...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Thompson, Julia Elizabeth Lennard, Simon Nicholas Wilton, Alison Jane Braddock, Peta Sally Helena Du Fou, Sarah Leila McCafferty, John Gerald Conroy, Louise Anne Tempest, Philip Ronald |
| description | The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor 1 (TGF
). More particularly, the invention is concerned with specific binding members which include the VH CDR3 of the antibody SL15 (the antibody formerly known as Kylie), especially the SL15 VH domain, which may be in combination with the SL15A or SL15S VL domains. Furthermore, the invention relates to use of such specific binding members in pharmaceutical preparations, particularly for the treatment of fibrotic disease, the modulation of wound healing and the treatment of cancer.
The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralizing activity for TGF and are useful in treating conditions associated with excess TGF activity, such as fibrosis, immune responses and tumor progression. |
| format | Patent |
| fullrecord | <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_06492497</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>06492497</sourcerecordid><originalsourceid>FETCH-uspatents_grants_064924973</originalsourceid><addsrcrecordid>eNrjZFANLkhNzkzLTFZIysxLycxLV8hNzU1KLSpWSMsvUghxd0tKLUk05GFgTUvMKU7lhdLcDApuriHOHrqlxQWJJal5JcXx6UWJIMrAzMTSyMTS3JgIJQDb8Cdt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Specific binding members for TGFbeta1</title><source>USPTO Issued Patents</source><creator>Thompson, Julia Elizabeth ; Lennard, Simon Nicholas ; Wilton, Alison Jane ; Braddock, Peta Sally Helena ; Du Fou, Sarah Leila ; McCafferty, John Gerald ; Conroy, Louise Anne ; Tempest, Philip Ronald</creator><creatorcontrib>Thompson, Julia Elizabeth ; Lennard, Simon Nicholas ; Wilton, Alison Jane ; Braddock, Peta Sally Helena ; Du Fou, Sarah Leila ; McCafferty, John Gerald ; Conroy, Louise Anne ; Tempest, Philip Ronald ; Cambridge Antibody Technology Limited</creatorcontrib><description>The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor 1 (TGF
). More particularly, the invention is concerned with specific binding members which include the VH CDR3 of the antibody SL15 (the antibody formerly known as Kylie), especially the SL15 VH domain, which may be in combination with the SL15A or SL15S VL domains. Furthermore, the invention relates to use of such specific binding members in pharmaceutical preparations, particularly for the treatment of fibrotic disease, the modulation of wound healing and the treatment of cancer.
The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralizing activity for TGF and are useful in treating conditions associated with excess TGF activity, such as fibrosis, immune responses and tumor progression.</description><language>eng</language><creationdate>2002</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6492497$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,776,798,881,64012</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6492497$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Thompson, Julia Elizabeth</creatorcontrib><creatorcontrib>Lennard, Simon Nicholas</creatorcontrib><creatorcontrib>Wilton, Alison Jane</creatorcontrib><creatorcontrib>Braddock, Peta Sally Helena</creatorcontrib><creatorcontrib>Du Fou, Sarah Leila</creatorcontrib><creatorcontrib>McCafferty, John Gerald</creatorcontrib><creatorcontrib>Conroy, Louise Anne</creatorcontrib><creatorcontrib>Tempest, Philip Ronald</creatorcontrib><creatorcontrib>Cambridge Antibody Technology Limited</creatorcontrib><title>Specific binding members for TGFbeta1</title><description>The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor 1 (TGF
). More particularly, the invention is concerned with specific binding members which include the VH CDR3 of the antibody SL15 (the antibody formerly known as Kylie), especially the SL15 VH domain, which may be in combination with the SL15A or SL15S VL domains. Furthermore, the invention relates to use of such specific binding members in pharmaceutical preparations, particularly for the treatment of fibrotic disease, the modulation of wound healing and the treatment of cancer.
The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralizing activity for TGF and are useful in treating conditions associated with excess TGF activity, such as fibrosis, immune responses and tumor progression.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2002</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZFANLkhNzkzLTFZIysxLycxLV8hNzU1KLSpWSMsvUghxd0tKLUk05GFgTUvMKU7lhdLcDApuriHOHrqlxQWJJal5JcXx6UWJIMrAzMTSyMTS3JgIJQDb8Cdt</recordid><startdate>20021210</startdate><enddate>20021210</enddate><creator>Thompson, Julia Elizabeth</creator><creator>Lennard, Simon Nicholas</creator><creator>Wilton, Alison Jane</creator><creator>Braddock, Peta Sally Helena</creator><creator>Du Fou, Sarah Leila</creator><creator>McCafferty, John Gerald</creator><creator>Conroy, Louise Anne</creator><creator>Tempest, Philip Ronald</creator><scope>EFH</scope></search><sort><creationdate>20021210</creationdate><title>Specific binding members for TGFbeta1</title><author>Thompson, Julia Elizabeth ; Lennard, Simon Nicholas ; Wilton, Alison Jane ; Braddock, Peta Sally Helena ; Du Fou, Sarah Leila ; McCafferty, John Gerald ; Conroy, Louise Anne ; Tempest, Philip Ronald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_064924973</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2002</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Julia Elizabeth</creatorcontrib><creatorcontrib>Lennard, Simon Nicholas</creatorcontrib><creatorcontrib>Wilton, Alison Jane</creatorcontrib><creatorcontrib>Braddock, Peta Sally Helena</creatorcontrib><creatorcontrib>Du Fou, Sarah Leila</creatorcontrib><creatorcontrib>McCafferty, John Gerald</creatorcontrib><creatorcontrib>Conroy, Louise Anne</creatorcontrib><creatorcontrib>Tempest, Philip Ronald</creatorcontrib><creatorcontrib>Cambridge Antibody Technology Limited</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Thompson, Julia Elizabeth</au><au>Lennard, Simon Nicholas</au><au>Wilton, Alison Jane</au><au>Braddock, Peta Sally Helena</au><au>Du Fou, Sarah Leila</au><au>McCafferty, John Gerald</au><au>Conroy, Louise Anne</au><au>Tempest, Philip Ronald</au><aucorp>Cambridge Antibody Technology Limited</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Specific binding members for TGFbeta1</title><date>2002-12-10</date><risdate>2002</risdate><abstract>The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor 1 (TGF
). More particularly, the invention is concerned with specific binding members which include the VH CDR3 of the antibody SL15 (the antibody formerly known as Kylie), especially the SL15 VH domain, which may be in combination with the SL15A or SL15S VL domains. Furthermore, the invention relates to use of such specific binding members in pharmaceutical preparations, particularly for the treatment of fibrotic disease, the modulation of wound healing and the treatment of cancer.
The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralizing activity for TGF and are useful in treating conditions associated with excess TGF activity, such as fibrosis, immune responses and tumor progression.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_uspatents_grants_06492497 |
| source | USPTO Issued Patents |
| title | Specific binding members for TGFbeta1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T20%3A41%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Thompson,%20Julia%20Elizabeth&rft.aucorp=Cambridge%20Antibody%20Technology%20Limited&rft.date=2002-12-10&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E06492497%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |